Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.La Jolla Pharmaceutical Company has acquired global development and commercialization rights to GCS-100 from Solana Therapeutics.
Subscribe to our email newsletter
GCS-100 is an inhibitor of galectin-3, a novel molecular target implicated in cancer and chronic organ failure.
Galectin-3 plays a key role in the immune system’s response to cancer and tissue injury, making specific inhibitors of galectin-3 attractive therapeutic candidates for a range of diseases.
GCS-100’s ongoing development as an anti-cancer and anti-fibrotic agent is supported by extensive preclinical and clinical investigation, including Phase 1 and Phase 2 clinical trials involving more than 140 patients.
As a part of the acquisition, George Tidmarsh, the former CEO of Solana, was appointed as the company’s president and CEO.
"Having been involved in the clinical development of GCS-100 over the past several years, I am thrilled to have the opportunity to continue this compound’s development," Tidmarsh said.
"Targeting galectin-3 holds great promise in the treatment of a broad range of life-threatening conditions, and, with GCS-100, we have the most advanced galectin-3-targeting compound in development."